Targeting macrophages: therapeutic approaches in cancer
L Cassetta, JW Pollard - Nature reviews Drug discovery, 2018 - nature.com
Infiltration of macrophages in solid tumours is associated with poor prognosis and correlates
with chemotherapy resistance in most cancers. In mouse models of cancer, macrophages …
with chemotherapy resistance in most cancers. In mouse models of cancer, macrophages …
Role of inflammation in diabetic retinopathy
A Rübsam, S Parikh, PE Fort - International journal of molecular sciences, 2018 - mdpi.com
Diabetic retinopathy is a common complication of diabetes and remains the leading cause of
blindness among the working-age population. For decades, diabetic retinopathy was …
blindness among the working-age population. For decades, diabetic retinopathy was …
[HTML][HTML] Targeted immunotherapy for autoimmune disease
SM Jung, WU Kim - Immune network, 2022 - ncbi.nlm.nih.gov
In the past few decades, biological drugs and small molecule inhibitors targeting
inflammatory cytokines, immune cells, and intracellular kinases have become the standard …
inflammatory cytokines, immune cells, and intracellular kinases have become the standard …
Ferroptosis: a double-edged sword mediating immune tolerance of cancer
Q Dang, Z Sun, Y Wang, L Wang, Z Liu, X Han - Cell death & disease, 2022 - nature.com
The term ferroptosis was put forward in 2012 and has been researched exponentially over
the past few years. Ferroptosis is an unconventional pattern of iron-dependent programmed …
the past few years. Ferroptosis is an unconventional pattern of iron-dependent programmed …
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
DN Khalil, EL Smith, RJ Brentjens… - Nature reviews Clinical …, 2016 - nature.com
In the past decade, advances in the use of monoclonal antibodies (mAbs) and adoptive
cellular therapy to treat cancer by modulating the immune response have led to …
cellular therapy to treat cancer by modulating the immune response have led to …
CD40 agonist antibodies in cancer immunotherapy
RH Vonderheide - Annual review of medicine, 2020 - annualreviews.org
CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily.
Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and …
Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and …
Platelets as key factors in inflammation: focus on CD40L/CD40
F Cognasse, AC Duchez, E Audoux… - Frontiers in …, 2022 - frontiersin.org
Platelets are anucleate cytoplasmic fragments derived from the fragmentation of medullary
megakaryocytes. Activated platelets adhere to the damaged endothelium by means of …
megakaryocytes. Activated platelets adhere to the damaged endothelium by means of …
Immune checkpoint inhibitors: basics and challenges
Cancer is one of the most deadly diseases in the modern world. The last decade has
witnessed dramatic advances in cancer treatment through immunotherapy. One extremely …
witnessed dramatic advances in cancer treatment through immunotherapy. One extremely …
Targeting co-stimulatory molecules in autoimmune disease
NM Edner, G Carlesso, JS Rush… - Nature Reviews Drug …, 2020 - nature.com
Therapeutic targeting of immune checkpoints has garnered significant attention in the area
of cancer immunotherapy, in which efforts have focused in particular on cytotoxic T …
of cancer immunotherapy, in which efforts have focused in particular on cytotoxic T …
[HTML][HTML] Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond
JL Karnell, SA Rieder, R Ettinger, R Kolbeck - Advanced drug delivery …, 2019 - Elsevier
CD40 is a TNF receptor superfamily member expressed on both immune and non-immune
cells. Interactions between B cell-expressed CD40 and its binding partner, CD40L …
cells. Interactions between B cell-expressed CD40 and its binding partner, CD40L …